Avacincaptad pegol
Based on 1 Customer Validation
Avacincaptad pegol (Izervay) is a selective inhibitor targeting complement component C5, and is a pegylated ribonucleic acid aptamer. Avacincaptad pegol inhibits the cleavage of C5 into pro-inflammatory C5a and C5b, which forms the membrane attack complex (C5b-9), thereby reducing inflammatory cell recruitment and retinal cell damage. Avacincaptad pegol can slow the growth of geographic atrophy (GA) lesions and reduce the risk of persistent vision loss. Avacincaptad pegol can be used in research of geographic atrophy associated with age-related macular degeneration (AMD) and has been approved by the FDA.
For research use only. We do not sell to patients.
- Purity : 92.19%
- CAS No.: 1613641-69-2
- Molecular Weight:52603 (Approximately)
-
Storage:
-20°C, sealed storage, away from moisture
* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)
Biological Activity
Description
IC50 & Target
|
C5 |
In Vitro
Avacincaptad pegol exerts its complement inhibitory activity by specifically binding to complement component C5, inhibiting its cleavage into pro-inflammatory C5a and C5b, which forms the membrane attack complex (MAC), thus blocking the terminal steps of the complement cascade[1].
Avacincaptad pegol can inhibit the damage to retinal pigment epithelial (RPE) cells caused by the complement activation product C5b-9, reduce lysosomal overload and the release of pro-inflammatory factors, maintain the stability of RPE cell function, and is associated with the improvement of pathological processes related to age-related macular degeneration (AMD)[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
In Vivo
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Cynomolgus macaques (Macaca fascicularis) (male, 2.9-6.6 kg, 3.4-5.0 years old) sodium iodate-induced dry age-related macular degeneration (AMD) with geographic atrophy (GA) model[2]
-
Dosage:Initial 1.5 mg/eye ubsequent doses adjusted to 1 mg/eye (phosphate-buffered saline)
-
Administration:16 weeks
-
Result:The mean GA area in Avacincaptad pegol-treated eyes (11.4 ± 4.0 mm2) was reduced by approximately 36% compared with vehicle-treated eyes (18.9 ± 6.6 mm2), though the difference was not statistically significant.
Avacincaptad pegol did not alter the thinning of total retinal thickness or central macular thickness induced by sodium iodate. No choroidal neovascularization (CNV) was observed in either the treatment or vehicle group.
Choroidal capillary (CC) leakage under or around the macula was detected in both groups, with no statistically significant difference in the incidence of CC leakage between the two groups.
Clinical Trial
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
Chemical Information
-
CAS No. 1613641-69-2
-
Appearance Solid
-
Molecular Weight 52603 (Approximately)
-
Color White to off-white
-
SMILES
[Avacincaptad pegol]
-
Synonyms
Izervay
-
Sequence
Poly(oxy-1,2-ethanediyl), α-hydro-ω-methoxy-, 5′-ether with RNA ((2′-deoxy-2′-fluoro)C-Gm-(2′-deoxy-2′-fluoro)C-(2′-deoxy-2′-fluoro)C-G-(2′-deoxy-2′-fluoro)C-Gm-Gm-(2′-deoxy-2′-fluoro)U-(2′-deoxy-2′-fluoro)C-(2′-deoxy-2′-fluoro)U-(2′-deoxy-2′-fluoro)C-Am-Gm-Gm-(2′-deoxy-2′-fluoro)C-G-(2′-deoxy-2′-fluoro)C-(2′-deoxy-2′-fluoro)U-Gm-Am-Gm-(2′-deoxy-2′-fluoro)U-(2′-deoxy-2′-fluoro)C-(2′-deoxy-2′-fluoro)U-Gm-Am-Gm-(2′-deoxy-2′-fluoro)U-(2′-deoxy-2′-fluoro)U-(2′-deoxy-2′-fluoro)U-A-(2′-deoxy-2′-fluoro)C-(2′-deoxy-2′-fluoro)C-(2′-deoxy-2′-fluoro)U-Gm-(2′-deoxy-2′-fluoro)C-Gm-(3′→3′)-dT) 5′-[6-[[(2,3-dihydroxypropoxy)carbonyl]amino]hexyl hydrogen phosphate] (2:1)
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
-20°C, sealed storage, away from moisture
* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)
Protocols
-
Zymosan-Induced Peritonitis
Zymosan-induced peritonitis is a sterile acute-inflammation model produced by intraperitoneal injection of zymosan, a yeast cell-wall particle preparation, followed by quantification of leukocyte recruitment and soluble inflammatory mediators in peritoneal lavage fluid. Low-dose zymosan peritonitis is commonly used as a self-resolving acute inflammation model in which neutrophil recruitment occurs early and monocyte/macrophage accumulation follows later. The assay readouts include total peritoneal leukocyte number, differential neutrophil and monocyte/macrophage counts, peritoneal cytokines and chemokines, plasma or peritoneal exudation, and optional lipidomic or metabolomic changes during inflammation and resolution. Early neutrophil recruitment after zymosan depends strongly on complement and mast-cell C5a receptor signaling, whereas later monocyte recruitment is linked to MCP-1/CCL2 production.
-
Research Protocol for Inflammation-related Diseases
The NLRP3 inflammasome is a cytosolic innate immune signaling platform that integrates priming signals and danger-signal activation to promote caspase-1 activation, maturation of IL-1β and IL-18, and gasdermin D-mediated pyroptotic cell death. The core experimental logic is to determine whether inflammatory disease phenotypes are driven by increased NLRP3 expression, ASC-containing inflammasome assembly, caspase-1 cleavage, GSDMD cleavage, and extracellular release of IL-1β/IL-18 rather than by nonspecific cell injury alone. The pathway is strongly linked to inflammation-related disease phenotypes because monosodium urate crystals activate NALP3/NLRP3 inflammasome signaling in gout-like crystal inflammation, cholesterol crystals activate NLRP3 inflammasomes in atherogenesis models, and DSS-induced intestinal inflammation has been reported to involve NLRP3 inflammasome activity. However, experimental colitis studies also show context-dependent protective effects of NLRP3 inflammasome co
Purity & Documentation
-
Data Sheet (276 KB)
-
SDS (252 KB)
- English - EN (252 KB)
- Français - FR (252 KB)
- Deutsch - DE (252 KB)
- Norwegian - NO (252 KB)
- Español - ES (252 KB)
- Swedish - SV (252 KB)
- Italian - IT (252 KB)
- Korean - KR (252 KB)
- Portuguese - PT (252 KB)
-
Handling Instructions (1518 KB)
References
[1]. Danzig CJ, et al. C5 inhibitor avacincaptad pegol treatment for geographic atrophy: A comprehensive review. Immunotherapy. 2024;16(12):779-790. [Content Brief]
[2]. Fujii R, et al. Intravitreal Administration of Avacincaptad Pegol in a Nonhuman Primate Model of Dry Age-Related Macular Degeneration. Pharmacol Res Perspect. 2025 Feb;13(1):e70052. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)